Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Resmetirom is the first drug to show both MASH resolution and fibrosis improvement in a late-stage clinical trial.
The findings could potentially lead to the first FDA approval of a treatment for fatty liver disease.
An FDA advisory committee expressed concerns about the safety of the fatty liver disease treatment.
VK2809 and pegozafermin are among several medications coming through the pipeline for fatty liver disease
Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.
A companion study will look at liver biopsy results to confirm these findings from noninvasive tests.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.